Hidradenitis suppurativa (HS) was associated with a significantly increased risk for cancer, according to the findings of a recent nationwide population-based cohort study, including several specific cancers such as Hodgkin lymphoma and nonmelanoma skin cancer.
Using data from the Korean Health Insurance Review and Assessment Service database, the researchers identified 22,468 patients diagnosed with HS between January 1, 2009 and December 31, 2017 and 179,734 controls matched by age, sex, index year, and insurance type. The mean age was 33.63 years and 63.7% of patients in both groups were male.
HS Disease Trajectory Includes Several Comorbidities
Almost 10% of HS Patients Have Comorbid Inflammatory Eye Disease
Are Biologic Therapies Safe for Patients With Cancer?
The researchers calculated overall and specific cancer incidence rates per 100,000 person-years, as well as the risk of cancers, and compared these between the HS and matched-control cohorts.
Among patients with HS, the adjusted hazard ratio (aHR) of overall cancer was 1.28 (95% CI, 1.15-1.42), the researchers wrote. They also found patients with HS had significantly higher risk for Hodgkin lymphoma (aHR, 5.08; 95% CI, 1.21-21.36), oral cavity and pharyngeal cancer (aHR 3.10; 95% CI, 1.60-6.02), central nervous system cancer (aHR, 2.40; 95% CI, 1.22-4.70), nonmelanoma skin cancer (HR, 2.06; 95% CI, 1.12-3.79), prostate cancer (aHR, 2.05; 95% CI, 1.30-3.24), and colorectal cancer (aHR, 1.45; 95% CI, 1.09-1.93).
“More intense cancer surveillance may be warranted in patients with HS,” the researchers concluded.
Jung JM, Lee KH, Kim Y, et al. Assessment of overall and specific cancer risks in patients with hidradenitis suppurativa. JAMA Dermatol. Published online May 27, 2020. doi:10.1001/jamadermatol.2020.1422